Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Effectiveness and Safety of Different Oral Anticoagulants with P-glycoprotein/ CYP3A4 Inhibitors: A Network Meta-analysis

Author(s): Siyu Yang, Ye Xu, Yang Zhang, Dandan Li* and Xingang Li*

Volume 30, Issue 15, 2024

Published on: 22 March, 2024

Page: [1167 - 1177] Pages: 11

DOI: 10.2174/0113816128293940240315073345

Price: $65

Abstract

Background: Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs.

Methods: Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding. Secondary outcomes were stroke/systemic embolism (SE), all-cause mortality, any bleeding as well as intracranial hemorrhage (ICH). We estimated summary odds ratios (OR) with 95% credible intervals (CI) using pairwise and network meta-analysis with random effects.

Results: A total of 11 studies involving 37,973 patients were included. When concomitantly used with P-pg/ CYP3A4 inhibitors, network meta-analysis indicated that dabigatran, apixaban, and edoxaban were associated with significantly lower risk of major bleeding compared to rivaroxaban, with ORs of 0.56, 0.51 and 0.48, respectively. Rivaroxaban and dabigatran were associated with a significantly increased risk of GI bleeding than warfarin, apixaban and edoxaban. Dabigatran and apixaban were linked with significantly lower risk of any bleeding compared with warfarin (ORs were 0.75 and 0.68, respectively) or rivaroxaban (ORs were 0.67 and 0.60, respectively). Apixaban (OR 0.32) and edoxaban (OR 0.35) were associated with a lower risk of ICH compared with warfarin. There was no difference between any OACs in terms of stroke/SE or all-cause mortality.

Conclusion: When concomitantly used with P-gp/CYP3A4 inhibitors, apixaban and edoxaban were associated with a lower risk of bleeding, though no significant difference in effectiveness was observed among all OACs.

« Previous Next »
[1]
Kuroda M, Tamiya E, Nose T, et al. Effect of 15-mg edoxaban on clinical outcomes in 3 age strata in older patients with atrial fibrillation. JAMA Cardiol 2022; 7(6): 583-90.
[http://dx.doi.org/10.1001/jamacardio.2022.0480] [PMID: 35416910]
[2]
Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145(4): 242-55.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.056355] [PMID: 34985309]
[3]
January CT, Wann LS, Calkins H. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 2019; 140(2): e125-52.
[http://dx.doi.org/10.1161/CIR.0000000000000665]
[4]
Wang X, Ma Y, Hui X, et al. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. Cochrane Libr 2023; 2023(4): CD010956.
[http://dx.doi.org/10.1002/14651858.CD010956.pub3] [PMID: 37058421]
[5]
Van der Linden L, Vanassche T, Van Cutsem E, Van Aelst L, Verhamme P. Pharmacokinetic drug-drug interactions with direct anticoagulants in the management of cancer-associated thrombosis. Br J Clin Pharmacol 2023; 89(8): 2369-76.
[http://dx.doi.org/10.1111/bcp.15785] [PMID: 37170893]
[6]
Naung Tun H, Kyaw MT, Rafflenbeul E, López Suástegui X. Role of direct oral anticoagulants for post-operative venous thromboembolism prophylaxis. Eur Cardiol 2022; 17: e11.
[http://dx.doi.org/10.15420/ecr.2021.55] [PMID: 35620356]
[7]
Cohen AT, Sah J, Dhamane AD, et al. Effectiveness and safety of apixaban versus warfarin in venous thromboembolism patients with chronic kidney disease. Thromb Haemost 2022; 122(6): 926-38.
[http://dx.doi.org/10.1055/s-0041-1740254] [PMID: 34963185]
[8]
Pirmohamed M. Warfarin: Almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62(5): 509-11.
[http://dx.doi.org/10.1111/j.1365-2125.2006.02806.x] [PMID: 17061959]
[9]
Ferrari F, da Silveira AD, Martins VM, Franzoni LT, Zimerman LI, Stein R. Direct-acting oral anticoagulants in atrial fibrillation. Cardiol Rev 2021; 29(3): 120-30.
[http://dx.doi.org/10.1097/CRD.0000000000000312] [PMID: 32332235]
[10]
Bovio JA, Smith SM, Gums JG. Dabigatran etexilate: A novel oral thrombin inhibitor for thromboembolic disease. Ann Pharmacother 2011; 45(5): 603-14.
[http://dx.doi.org/10.1345/aph.1P644] [PMID: 21540406]
[11]
Roberti R, Iannone LF, Palleria C, et al. Direct oral anticoagulants: From randomized clinical trials to real-world clinical practice. Front Pharmacol 2021; 12: 684638.
[http://dx.doi.org/10.3389/fphar.2021.684638] [PMID: 34122113]
[12]
Zhang Y, Souverein PC, Gardarsdottir H, van den Ham HA, Maitland-van der Zee AH, de Boer A. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol 2020; 86(6): 1150-64.
[http://dx.doi.org/10.1111/bcp.14227] [PMID: 32022295]
[13]
Hindley B, Lip GYH, McCloskey AP, Penson PE. Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. Expert Opin Drug Metab Toxicol 2023; 19(12): 911-23.
[http://dx.doi.org/10.1080/17425255.2023.2287472] [PMID: 37991392]
[14]
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41(4): 543-603.
[http://dx.doi.org/10.1093/eurheartj/ehz405] [PMID: 31504429]
[15]
Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice - European society for vascular surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 2021; 61(1): 9-82.
[http://dx.doi.org/10.1016/j.ejvs.2020.09.023] [PMID: 33334670]
[16]
Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: Evidence and unresolved issues. Lancet 2020; 396(10264): 1767-76.
[http://dx.doi.org/10.1016/S0140-6736(20)32439-9] [PMID: 33248499]
[17]
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS). Eur Heart J 2021; 42(5): 373-498.
[http://dx.doi.org/10.1093/eurheartj/ehaa612] [PMID: 32860505]
[18]
Steffel J, Collins R, Antz M, et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23(10): 1612-76.
[http://dx.doi.org/10.1093/europace/euab065] [PMID: 33895845]
[19]
Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE. Chest 2021; 160(6): e545-608.
[http://dx.doi.org/10.1016/j.chest.2021.07.055] [PMID: 34352278]
[20]
Harrington J, Carnicelli AP, Hua K, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF. Circulation 2023; 147(23): 1748-57.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.122.062752] [PMID: 37042255]
[21]
Foerster KI, Hermann S, Mikus G, Haefeli WE. Drug-drug interactions with direct oral anticoagulants. Clin Pharmacokinet 2020; 59(8): 967-80.
[http://dx.doi.org/10.1007/s40262-020-00879-x] [PMID: 32157630]
[22]
Mar PL, Gopinathannair R, Gengler BE, et al. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol 2022; 15(6): e007956.
[http://dx.doi.org/10.1161/CIRCEP.121.007956] [PMID: 35622425]
[23]
Hanigan S, Park JM. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction. Expert Opin Drug Metab Toxicol 2022; 18(3): 1-14.
[http://dx.doi.org/10.1080/17425255.2022.2074397] [PMID: 35543017]
[24]
Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): From pharmacological to clinical practice. Pharmaceutics 2022; 14(6): 1120.
[http://dx.doi.org/10.3390/pharmaceutics14061120] [PMID: 35745692]
[25]
Herink MC, Zhuo YF, Williams CD, DeLoughery TG. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs 2019; 79(15): 1625-34.
[http://dx.doi.org/10.1007/s40265-019-01183-0] [PMID: 31440911]
[26]
Grymonprez M, Vanspranghe K, Capiau A, Boussery K, Steurbaut S, Lahousse L. Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis. Br J Clin Pharmacol 2022; 88(7): 3039-51.
[http://dx.doi.org/10.1111/bcp.15265] [PMID: 35132677]
[27]
Grymonprez M, Vanspranghe K, Steurbaut S, De Backer TL, Lahousse L. Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation using P-gp and/or CYP450-interacting drugs: A systematic review and meta-analysis. Cardiovasc Drugs Ther 2023; 37(4): 781-91.
[http://dx.doi.org/10.1007/s10557-021-07279-8] [PMID: 34637052]
[28]
Harskamp RE, Teichert M, Lucassen WAM, van Weert HCPM, Lopes RD. Impact of polypharmacy and P-Glycoprotein- and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation. Cardiovasc Drugs Ther 2019; 33(5): 615-23.
[http://dx.doi.org/10.1007/s10557-019-06907-8] [PMID: 31520256]
[29]
Kim IS, Kim HJ, Yu HT, et al. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. J Cardiol 2019; 73(6): 515-21.
[http://dx.doi.org/10.1016/j.jjcc.2018.12.018] [PMID: 30770140]
[30]
Corsini A, Ferri N, Proietti M, Boriani G. Edoxaban and the issue of drug-drug interactions: From pharmacology to clinical practice. Drugs 2020; 80(11): 1065-83.
[http://dx.doi.org/10.1007/s40265-020-01328-6] [PMID: 32504376]
[31]
Bezabhe WM, Bereznicki LR, Radford J, et al. Five-year trends in potential drug interactions with direct-acting oral anticoagulants in patients with atrial fibrillation: An australian-wide study. J Clin Med 2020; 9(11): 3568.
[http://dx.doi.org/10.3390/jcm9113568] [PMID: 33167560]
[32]
Holt A, Strange JE, Rasmussen PV, et al. Bleeding risk following systemic fluconazole or topical azoles in patients with atrial fibrillation on apixaban, rivaroxaban, or dabigatran. Am J Med 2022; 135(5): 595-602.e5.
[http://dx.doi.org/10.1016/j.amjmed.2021.11.008] [PMID: 34861201]
[33]
Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-drug interactions in the treatment of cancer-associated venous thromboembolism with direct oral anticoagulants. Semin Thromb Hemost 2023; s-0043-s-1762596.
[http://dx.doi.org/10.1055/s-0043-1762596] [PMID: 36731488]
[34]
Goldstein R, Jacobs AR, Zighan L, Gronich N, Bialer M, Muszkat M. Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: Potential implications on DOAC treatment. CNS Drugs 2023; 37(3): 203-14.
[http://dx.doi.org/10.1007/s40263-023-00990-0] [PMID: 36869199]
[35]
Gronich N, Stein N, Muszkat M. Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: Nested case-control study. Clin Pharmacol Ther 2021; 110(6): 1526-36.
[http://dx.doi.org/10.1002/cpt.2369] [PMID: 34287842]
[36]
Ngo LT, Yang S, Tran QT, Kim SK, Yun H, Chae J. Effects of carbamazepine and phenytoin on pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics 2020; 12(11): 1040.
[http://dx.doi.org/10.3390/pharmaceutics12111040] [PMID: 33143037]
[37]
Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res 2022; 218: 24-34.
[http://dx.doi.org/10.1016/j.thromres.2022.08.007] [PMID: 35985100]
[38]
Stöllberger C, Finsterer J. Update on drug interactions with non-vitamin-K-antagonist oral anticoagulants for stroke prevention in elderly patients. Expert Rev Clin Pharmacol 2021; 14(5): 569-81.
[http://dx.doi.org/10.1080/17512433.2021.1908124] [PMID: 33757376]
[39]
Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 2020; 49(4): 636-43.
[http://dx.doi.org/10.1007/s11239-020-02037-3] [PMID: 31925665]
[40]
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[41]
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[42]
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[43]
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844]
[44]
Scaglione F. New oral anticoagulants: Comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013; 52(2): 69-82.
[http://dx.doi.org/10.1007/s40262-012-0030-9] [PMID: 23292752]
[45]
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162(11): 777-84.
[http://dx.doi.org/10.7326/M14-2385] [PMID: 26030634]
[46]
Higgins JPT, Altman DG, Gotzsche PC. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
[http://dx.doi.org/10.1136/bmj.d5928]
[47]
Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 2001; 54(10): 1046-55.
[http://dx.doi.org/10.1016/S0895-4356(01)00377-8] [PMID: 11576817]
[48]
Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. J Am Coll Cardiol 2014; 64(15): 1541-50.
[http://dx.doi.org/10.1016/j.jacc.2014.07.967] [PMID: 25301455]
[49]
Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4): e203593.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.3593] [PMID: 32329770]
[50]
Holm J, Mannheimer B, Malmström RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol 2021; 77(3): 409-19.
[http://dx.doi.org/10.1007/s00228-020-03015-7] [PMID: 33029651]
[51]
Xu Y, Chang AR, Inker LA, McAdams-DeMarco M, Grams ME, Shin JI. Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J Am Heart Assoc 2022; 11(14): e025723.
[http://dx.doi.org/10.1161/JAHA.122.025723] [PMID: 35861836]
[52]
Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: A subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015; 36(33): 2239-45.
[http://dx.doi.org/10.1093/eurheartj/ehv201] [PMID: 25971288]
[53]
Bistervels IM, Bavalia R, Gebel M, et al. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. J Thromb Haemost 2022; 20(6): 1376-84.
[http://dx.doi.org/10.1111/jth.15692] [PMID: 35253983]
[54]
Washam JB, Hellkamp AS, Lokhnygina Y, et al. Efficacy and safety of rivaroxaban versus warfarin in patients taking nondihydropyridine calcium channel blockers for atrial fibrillation (from the ROCKET AF trial). Am J Cardiol 2017; 120(4): 588-94.
[http://dx.doi.org/10.1016/j.amjcard.2017.05.026] [PMID: 28645473]
[55]
Gandhi SK, Reiffel JA, Boiron R, Wieloch M. Risk of major bleeding in patients with atrial fibrillation taking dronedarone in combination with a direct acting oral anticoagulant (from a U.S. claims database). Am J Cardiol 2021; 159: 79-86.
[http://dx.doi.org/10.1016/j.amjcard.2021.08.015] [PMID: 34656316]
[56]
Friberg L. Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol 2018; 264: 85-90.
[http://dx.doi.org/10.1016/j.ijcard.2018.02.055] [PMID: 29776576]
[57]
Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm 2014; 11(6): 925-32.
[http://dx.doi.org/10.1016/j.hrthm.2014.03.006] [PMID: 24833235]
[58]
Wanat MA, Wang X, Paranjpe R, et al. Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. Res Pract Thromb Haemost 2019; 3(4): 674-83.
[http://dx.doi.org/10.1002/rth2.12221] [PMID: 31624787]
[59]
Grześk G, Rogowicz D, Wołowiec Ł, et al. The clinical significance of drug-food interactions of direct oral anticoagulants. Int J Mol Sci 2021; 22(16): 8531.
[http://dx.doi.org/10.3390/ijms22168531] [PMID: 34445237]
[60]
Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 2017; 31(4): 193-203.
[http://dx.doi.org/10.1016/j.blre.2017.02.001] [PMID: 28196633]
[61]
Desai J, Kolb J, Weitz J, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants - defining the issues and the management strategies. Thromb Haemost 2013; 110(8): 205-12.
[http://dx.doi.org/10.1160/TH13-02-0150] [PMID: 23702623]
[62]
Oh HJ, Ryu KH, Park BJ, Yoon BH. The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants. Medicine 2021; 100(11): e25216.
[http://dx.doi.org/10.1097/MD.0000000000025216] [PMID: 33726018]
[63]
Gillis AM, Kates RE. Clinical pharmacokinetics of the newer antiarrhythmic agents. Clin Pharmacokinet 1984; 9(5): 375-403.
[http://dx.doi.org/10.2165/00003088-198409050-00001] [PMID: 6437721]
[64]
Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986; 11(6): 425-49.
[http://dx.doi.org/10.2165/00003088-198611060-00002] [PMID: 3542336]
[65]
Dorian P. Clinical pharmacology of dronedarone: Implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 2010; 15(4_suppl) (Suppl.): 15S-8S.
[http://dx.doi.org/10.1177/1074248410367792] [PMID: 20472816]
[66]
Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013; 78(2): 227-39.
[http://dx.doi.org/10.1016/j.gie.2013.04.179] [PMID: 23725876]
[67]
Yavuz B, Ayturk M, Ozkan S, et al. A real world data of dabigatran etexilate: Multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. J Thromb Thrombolysis 2016; 42(3): 399-404.
[http://dx.doi.org/10.1007/s11239-016-1361-4] [PMID: 27085540]
[68]
Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61(22): 2264-73.
[http://dx.doi.org/10.1016/j.jacc.2013.03.020] [PMID: 23562920]
[69]
Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123(21): 2363-72.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004747] [PMID: 21576658]
[70]
He Y, Wong ICK, Li X, et al. The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: A meta-analysis of observational studies. Br J Clin Pharmacol 2016; 82(1): 285-300.
[http://dx.doi.org/10.1111/bcp.12911] [PMID: 26889922]
[71]
Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017; 23(11): 1954-63.
[http://dx.doi.org/10.3748/wjg.v23.i11.1954] [PMID: 28373761]
[72]
Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176(11): 1662-71.
[http://dx.doi.org/10.1001/jamainternmed.2016.5954] [PMID: 27695821]
[73]
Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: A large population-based study. Gastroenterology 2017; 152(5): 1014-1022.e1.
[http://dx.doi.org/10.1053/j.gastro.2016.12.018] [PMID: 28043907]
[74]
Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf 2017; 16(6): 673-85.
[http://dx.doi.org/10.1080/14740338.2017.1325870] [PMID: 28467190]
[75]
Lupercio F, Romero J, Peltzer B, et al. Efficacy and safety outcomes of direct oral anticoagulants and amiodarone in patients with atrial fibrillation. Am J Med 2018; 131(5): 573.e1-8.
[http://dx.doi.org/10.1016/j.amjmed.2017.11.047] [PMID: 29274758]
[76]
Guo WQ, Chen XH, Tian XY, Li L. Differences in gastrointestinal safety profiles among novel oral anticoagulants: Evidence from a network meta-analysis. Clin Epidemiol 2019; 11: 911-21.
[http://dx.doi.org/10.2147/CLEP.S219335] [PMID: 31632152]
[77]
Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Circulation 2015; 132(3): 194-204.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013267] [PMID: 25995317]
[78]
Wang CL, Wu VCC, Chang KH, et al. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur Heart J Cardiovasc Pharmacother 2020; 6(3): 147-54.
[http://dx.doi.org/10.1093/ehjcvp/pvz035] [PMID: 31384926]
[79]
Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017; 318(13): 1250-9.
[http://dx.doi.org/10.1001/jama.2017.13883] [PMID: 28973247]
[80]
Sandhu RK, Islam S, Dover DC, et al. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes 2022; 8(2): 195-201.
[http://dx.doi.org/10.1093/ehjqcco/qcab002] [PMID: 33480405]
[81]
Ho CJ, Chen SH, Lin CH, Lu YT, Hsu CW, Tsai MH. Non-vitamin K oral anticoagulants and anti-seizure medications: A retrospective cohort study. Front Neurol 2021; 11: 588053.
[http://dx.doi.org/10.3389/fneur.2020.588053] [PMID: 33732201]
[82]
Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111(9): 4471-6.
[http://dx.doi.org/10.1182/blood-2007-11-123711] [PMID: 18316627]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy